ATE466854T1 - 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren - Google Patents

1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Info

Publication number
ATE466854T1
ATE466854T1 AT07787842T AT07787842T ATE466854T1 AT E466854 T1 ATE466854 T1 AT E466854T1 AT 07787842 T AT07787842 T AT 07787842T AT 07787842 T AT07787842 T AT 07787842T AT E466854 T1 ATE466854 T1 AT E466854T1
Authority
AT
Austria
Prior art keywords
ylpiperazine
ylmethanone
indole
derivatives
receptor modulators
Prior art date
Application number
AT07787842T
Other languages
English (en)
Inventor
Matthias Nettekoven
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE466854T1 publication Critical patent/ATE466854T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07787842T 2006-08-03 2007-07-24 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren ATE466854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06118419 2006-08-03
PCT/EP2007/057599 WO2008015125A1 (en) 2006-08-03 2007-07-24 1h-indol-6-yl-piperazin-1-yl-methanone-derivatives for use as h3 receptor modulators

Publications (1)

Publication Number Publication Date
ATE466854T1 true ATE466854T1 (de) 2010-05-15

Family

ID=38523371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07787842T ATE466854T1 (de) 2006-08-03 2007-07-24 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Country Status (9)

Country Link
US (1) US7514433B2 (de)
EP (1) EP2069331B1 (de)
JP (1) JP2009545551A (de)
CN (1) CN101490039A (de)
AT (1) ATE466854T1 (de)
CA (1) CA2658282A1 (de)
DE (1) DE602007006328D1 (de)
ES (1) ES2342851T3 (de)
WO (1) WO2008015125A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96424C2 (ru) 2005-09-16 2011-11-10 Янссен Фармацевтика Н.В. Циклопропил амины как модуляторы н3 рецепторов гистамина
AU2008223142A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Indole and benzothiophene compounds as modulators of the histamine H3 receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3188732B1 (de) 2014-09-05 2019-07-24 Merck Sharp & Dohme Corp. Tetrahydroisochinolinderivate als inhibitoren von diacylglycerid-o-acyltransferase 2
EP3188730B1 (de) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisochinolinderivate als inhibitoren von diacylglycerid-o-acyltransferase 2
CN109963561A (zh) 2016-11-18 2019-07-02 默沙东公司 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物
RU2019117556A (ru) 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
EP4255904A2 (de) * 2020-12-03 2023-10-11 Domain Therapeutics Par-2-inhibitoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6380201B1 (en) * 1997-08-05 2002-04-30 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
DE19934433A1 (de) 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
EP1539742B1 (de) 2002-06-24 2006-11-08 Schering Corporation Als histamin-h3-antagonisten geeignete indolderivate
GB0224083D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
CA2569611C (en) 2004-06-21 2012-12-11 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
BRPI0518222A (pt) 2004-10-19 2008-11-04 Hoffmann La Roche composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
AU2006207712A1 (en) 2005-01-19 2006-07-27 F. Hoffmann-La Roche Ag 5-aminoindole derivatives

Also Published As

Publication number Publication date
EP2069331B1 (de) 2010-05-05
WO2008015125A1 (en) 2008-02-07
CA2658282A1 (en) 2008-02-07
JP2009545551A (ja) 2009-12-24
ES2342851T3 (es) 2010-07-15
CN101490039A (zh) 2009-07-22
EP2069331A1 (de) 2009-06-17
US20080032976A1 (en) 2008-02-07
DE602007006328D1 (de) 2010-06-17
US7514433B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
NO20082096L (no) Azaindol-2-karboksamidderivativer
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA201000439A1 (ru) Бензотиазолы в качестве модуляторов рецептора грелина
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE481395T1 (de) Cyclohexylderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties